Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
Cipla
QuintilesIMS
Johnson and Johnson
Boehringer Ingelheim
Covington
Argus Health
Dow

Generated: January 22, 2019

DrugPatentWatch Database Preview

Mission Pharma Company Profile

« Back to Dashboard

What is the competitive landscape for MISSION PHARMA, and when can generic versions of MISSION PHARMA drugs launch?

MISSION PHARMA has fifteen approved drugs.

There are two US patents protecting MISSION PHARMA drugs.

There are ten patent family members on MISSION PHARMA drugs in seven countries and ten supplementary protection certificates in four countries.

Summary for Mission Pharma
International Patents:10
US Patents:2
Tradenames:14
Ingredients:12
NDAs:15

Drugs and US Patents for Mission Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mission Pharmacal Co CARBINOXAMINE MALEATE carbinoxamine maleate TABLET;ORAL 090756-001 May 27, 2011 AA RX No No ➤ Sign Up ➤ Sign Up
Mission Pharma LITHOSTAT acetohydroxamic acid TABLET;ORAL 018749-001 May 31, 1983 RX Yes Yes ➤ Sign Up ➤ Sign Up
Mission Pharma TINDAMAX tinidazole TABLET;ORAL 021618-002 May 17, 2004 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Mission Pharma UROCIT-K potassium citrate TABLET, EXTENDED RELEASE;ORAL 019071-002 Aug 31, 1992 AB RX Yes No ➤ Sign Up ➤ Sign Up
Mission Pharma TEXACORT hydrocortisone SOLUTION;TOPICAL 081271-001 Apr 17, 1992 RX No Yes ➤ Sign Up ➤ Sign Up
Mission Pharma PREDNISOLONE SODIUM PHOSPHATE prednisolone sodium phosphate SOLUTION;ORAL 091396-001 Sep 13, 2010 RX No Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Mission Pharma Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2004035004 ➤ Sign Up
European Patent Office 2277503 ➤ Sign Up
Canada 2495886 ➤ Sign Up
Australia 2003284275 ➤ Sign Up
World Intellectual Property Organization (WIPO) 03075884 ➤ Sign Up
Austria 541575 ➤ Sign Up
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Mission Pharma Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/008 Ireland ➤ Sign Up PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
C0038 France ➤ Sign Up PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
C0026 France ➤ Sign Up PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
C/GB12/028 United Kingdom ➤ Sign Up PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
C/GB08/020 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
C/GB95/010 United Kingdom ➤ Sign Up PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Johnson and Johnson
US Army
Mallinckrodt
Federal Trade Commission
Boehringer Ingelheim
McKinsey
Argus Health
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.